Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Better prognosis markers for prostate cancer found

18.02.2010
Measuring levels of the active form of the protein EGFR in the tumor and its vicinity can provide a more reliable prognosis for individuals with prostate cancer. This is what Umeå University researcher Peter Hammarsten and his associates write in a study in the leading scientific journal Clinical Cancer Research.

One of the major problems with prostate cancer is that, with today's prognosis markers, some 70-80 percent of patients wind up in a group where very little can be said about their prognosis.

Unfortunately, today no methods to are good enough determine which patients truly need treatment and which ones can get along fine without the difficult treatment. This in turn means that certain patients are over-treated with therapies that can lead to serious side effects and that other patients who really need intensive treatment do not get it or get it too late.

In a study recently published in the scientific journal Clinical Cancer Research, Hammarsten studied tissue biopsies from prostate tumors in 259 patients and found a new prognosis marker for prostate cancer. It is the active form of the protein EFGR (Epidermal Growth Factor Receptor) that was shown to provide information about the aggressiveness of the tumor, both when it is measured in the tumor or in the healthy tissue surrounding the tumor.

EGFR belongs to the same family as the prognosis marker HER2, which is used today for breast cancer to determine the aggressiveness of a tumor that is to be treated with inhibitors of HER2, that is, the drug Herceptin. In a similar way, it may be possible in the future to use the active form of EGFR to select patients with a poor prognosis and are suitable for treatment with inhibitors of EGFR. In order to use EGFR as a prognosis marker clinically in the future, further studies will need to target its expressions in other and larger material in prostate tumors.

Prostate cancer is the most common cancer form among men in Sweden. Every year some 10,000 men are diagnosed with prostate cancer. Some 2,500 of them will die of their disease. In other words, some patients have an aggressive fatal disease, whereas others have a slowly growing tumor that will not cause any major problems.

Reference: Peter Hammarsten, Amar Karalija, Andreas Josefsson, Stina Häggström Rudolfsson, Pernilla Wikström, Lars Egevad, Torvald Granfors, Pär Stattin and Anders Bergh. Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients. Clinical Cancer Research.

For more information, please contact PhD (medicine) and intern Peter Hammarsten, Department of Medical Bioscience, Umeå University at

Phone: +46 (0)90-785 15 97; mobile: +46 (0)70-517 42 62 ; e-mail: peter.hammarsten@medbio.umu.se

Pressofficer Bertil Born; +46-703886 058;bertil.born@adm.umu.se

Bertil Born | idw
Further information:
http://www.umu.se
http://www.vr.se

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Researchers invent tiny, light-powered wires to modulate brain's electrical signals

21.02.2018 | Life Sciences

The “Holy Grail” of peptide chemistry: Making peptide active agents available orally

21.02.2018 | Life Sciences

Atomic structure of ultrasound material not what anyone expected

21.02.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>